✦ LIBER ✦

Development of human bispecific antibodies against CD20/CD55 or CD20/CD59 for the treatment of Burkitt lymphoma

✍ Scribed by P. Macor; E. Secco; N. Mezzaroba; L. De Maso; P. Durigutto; T. Gaiotto; C. Garrovo; F. Biffi; S. Zorzet; D. Sblattero; F. Tedesco

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Characterization of a human bispecific a

✍ Paolo Macor; Nelly Mezzaroba; Luca De Maso; Chiara Garrovo; Stefania Biffi; Dani 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 80 KB

Neutralizing human antibodies against CD

✍ P. Macor; E. Piovan; S. Zorzet; C. Tripodo; R. Marzari; A. Amadori; F. Tedesco 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 77 KB

Immune consolidation after stem cell tra

✍ L.G. Lum; P. Davol; G. Colvin; R. Rathore; M. Abedi; E. Palushock; A. Olson; T. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 59 KB

Expression of the complement regulatory

✍ Mikio Kuraya; George Klein; Eva Klein; Eitan Yefenof 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 579 KB

The anti-CD20 antibody rituximab augment

✍ David J. Flavell; Sarah L. Warnes; Christine J. Bryson; Sarah A. Field; Armorel 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 548 KB

Characterization of a humanized anti-CD2

✍ Lan Wu; Chong Wang; Dapeng Zhang; Xunming Zhang; Weizhu Qian; Lei Zhao; Hao Wang 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 781 KB